Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHO

5 Jul 2017

Abstract excerpt

Immunotherapy with anti-GD2 antibody (Ab) ch14.18/CHO is effective for treatment of high-risk neuroblastoma (NB) patients and is mainly based on GD2-specific Ab-dependent cellular cytotoxicity (ADCC). Strategies to further enhance the efficacy are important and currently explored in prospective clinical trials randomizing ch14.18/CHO ± IL-2. Recently, expression of programmed death 1 (PD-1) inhibitory receptor by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to CAR-T cell therapy research
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29123953
DOI: 10.1080/2162402x.2017.1343775

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHOPMID 29123953Read ↗

State of the Art in Immunotherapy of NeuroblastomaSemantic proximity Read ↗

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read ↗

Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.Semantic proximity Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patientsSemantic proximity Read ↗

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survivalSemantic proximity Read ↗

Inhibition of autophagy enhances the antitumor efficacy of T/CAR T cell against neuroblastomaSemantic proximity Read ↗

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in <i>TH-MYCN</i> miceSemantic proximity Read ↗

Targeted inhibition of myeloid-derived suppressor cells in the tumor microenvironment by low-dose doxorubicin to improve immune efficacy in murine neuroblastomaSemantic proximity Read ↗

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with NeuroblastomaSemantic proximity Read ↗

Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15Semantic proximity Read ↗

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.